RecruitingNCT06459024

Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Master Framework For Relapse or Refractory Acute Myeloid Leukemia- IMPACT STREAM - A Prospective Observational Study of Treatment Outcomes

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Enrollment

4,000 participants

Start Date

Jun 28, 2024

Study Type

OBSERVATIONAL

Conditions

Acute Myeloid Leukemia, in Relapse

Summary

This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites

Eligibility

Min Age: 6 Years

Plain Language Summary

Simplified for easier understanding

This is a master framework (also called an umbrella trial) for people with acute myeloid leukemia (AML) whose cancer has relapsed (come back) or is refractory (not responding to treatment). The framework allows multiple experimental treatments to be tested within a single organized structure. **You may be eligible if...** - You have been diagnosed with AML according to current international standards - Your leukemia has relapsed, is refractory to treatment, or has progressed — including cases where minimal residual disease (trace cancer cells) has returned - You or your legal representative can give informed consent **You may NOT be eligible if...** - Your specific sub-study has additional exclusion criteria that apply to your situation - Certain experimental protocols within the framework exclude you based on prior treatments or co-enrollment in other trials Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERRegistration into the STREAM platform

All patients fulfilling eligibility criteria will be registered into the STREAM platform. Baseline and follow up information will be recorded for each patient enrolled. Each patient will be followed up according to normal clinical practice up to 4 years.

Locations(38)

University Hospital Aachen

Aachen, Germany

University Hospital Greifswald

Greifswald, Germany

University Hospital Halle

Halle, Germany

University Hospital of Rostock

Rostock, Germany

Policlinico Sant'Orsola-Malpighi

Bologna, BO, Italy

Ospedale "A. Perrino"

Brindisi, BR, Italy

ASST Spedali Civili

Brescia, BS, Italy

Azienda Ospedaliera S. Croce e Carle

Cuneo, CN, Italy

Ospedale Valduce

Como, CO, Italy

ASST Cremona

Cremona, CR, Italy

AOU Universitaria Arcispedale Sant'Anna

Ferrara, FE, Italy

IRCCS Ospedale Policlinico San Martino

Genova, GE, Italy

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

Milan, MI, Italy

ASST Grande Ospedale Metropolitano Niguarda

Milan, MI, Italy

Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello

Palermo, PA, Italy

Presidio Ospedaliero "Santo Spirito"

Pescara, PE, Italy

Ospedale Santa Maria della Misericordia

Perugia, PG, Italy

Ospedale Santa Maria delle Croci

Ravenna, RA, Italy

Fondazione Policlinico Tor Vergata

Roma, RM, Italy

Policlinico Umberto I

Roma, RM, Italy

Policlinico Universitario Fondazione Agostino Gemelli

Roma, RM, Italy

Ospedale Sant'Andrea

Roma, RM, Italy

Ospedale infermi di Rimini

Rimini, RN, Italy

AOU San Giovanni di Dio e Ruggi d'Aragona

Salerno, SA, Italy

AOU Città della Salute e della Scienza di Torino

Torino, TO, Italy

AO Ordine Mauriziano

Torino, TO, Italy

IOV Istituto Oncologico Veneto

Castelfranco Veneto, TV, Italy

ASST Valle Olona

Busto Arsizio, VA, Italy

AOU Careggi

Florence, Italy

IRST Istituto Romagnolo per lo Studio dei Tumori Dino Amadori

Meldola, Italy

Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli

Naples, Italy

AOU Maggiore della Carità

Novara, Italy

Azienda Ospedale-Università Padova

Padova, Italy

Ospedale San Bortolo

Vicenza, Italy

The Hospital of Lithuanian University of Health Sciences Kauno Klinikos

Kaunas, Lithuania

University Clinical Center in Gdańsk

Gdansk, Poland

Fundeni Clinical Institute

Bucharest, Romania

University Hospital La Fe

Valencia, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06459024

Related Trials

Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT047164521 location

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

NCT0573518444 locations

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

NCT060172587 locations

Venetoclax to Augment Epigenetic Modification and Chemotherapy

NCT053174031 location

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT055973061 location